 Neuromyelitis Optica
"Neuromyelitis Optica" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.
| Descriptor ID |
D009471
|
| MeSH Number(s) |
C10.114.375.600.500 C10.114.375.800 C10.292.700.550.500 C10.314.350.600.500 C10.314.350.800 C11.640.576.695 C20.111.258.250.550.500 C20.111.258.250.775
|
| Concept/Terms |
Neuromyelitis Optica- Neuromyelitis Optica
- NMO Spectrum Disorder
- NMO Spectrum Disorders
- Neuromyelitis Optica (NMO) Spectrum Disorder
- Neuromyelitis Optica Spectrum Disorders
- Neuromyelitis Optica (NMO) Spectrum Disorders
- Devic Neuromyelitis Optica
- Devic Neuromyelitis Opticas
- Neuromyelitis Optica, Devic
- Neuromyelitis Opticas, Devic
- Devic Disease
- Disease, Devic
- Devic Syndrome
- Syndrome, Devic
- Devic's Syndrome
- Devics Syndrome
- Syndrome, Devic's
- Devic's Neuromyelitis Optica
- Devics Neuromyelitis Optica
- Neuromyelitis Optica, Devic's
- Neuromyelitis Optica Spectrum Disorder
- Devic's Disease
- Devics Disease
- Disease, Devic's
|
Below are MeSH descriptors whose meaning is more general than "Neuromyelitis Optica".
Below are MeSH descriptors whose meaning is more specific than "Neuromyelitis Optica".
This graph shows the total number of publications written about "Neuromyelitis Optica" by people in this website by year, and whether "Neuromyelitis Optica" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 7 | 1 | 8 | | 2012 | 9 | 0 | 9 | | 2013 | 5 | 1 | 6 | | 2014 | 5 | 0 | 5 | | 2015 | 7 | 0 | 7 | | 2016 | 6 | 0 | 6 | | 2017 | 5 | 3 | 8 | | 2018 | 1 | 0 | 1 | | 2019 | 6 | 0 | 6 | | 2020 | 7 | 0 | 7 | | 2021 | 5 | 0 | 5 | | 2022 | 8 | 0 | 8 | | 2023 | 13 | 0 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuromyelitis Optica" by people in Profiles.
-
Samadzadeh S, Olesen MN, Wirenfeldt M, M?ller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N. Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects. Mult Scler. 2023 Dec; 29(14):1721-1735.
-
McBride HJ, Frazer-Abel A, Thiemann S, Lehto SG, Hutterer KM, Liu J. Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD. Ann Hematol. 2023 Dec; 102(12):3299-3309.
-
Kim HJ, Aktas O, Patterson KR, Korff S, Kunchok A, Bennett JL, Weinshenker BG, Paul F, Hartung HP, Cimbora D, Smith MA, Mittereder N, Rees WA, She D, Cree BAC. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. Ann Clin Transl Neurol. 2023 12; 10(12):2413-2420.
-
Remlinger J, Bagnoud M, Meli I, Massy M, Linington C, Chan A, Bennett JL, Hoepner R, Enzmann V, Salmen A. Modelling MOG antibody-associated disorder and neuromyelitis optica spectrum disorder in animal models: Spinal cord manifestations. Mult Scler Relat Disord. 2023 Oct; 78:104892.
-
Remlinger J, Bagnoud M, Meli I, Massy M, Hoepner R, Linington C, Chan A, Bennett JL, Enzmann V, Salmen A. Modeling MOG Antibody-Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations. Neurol Neuroimmunol Neuroinflamm. 2023 09; 10(5).
-
Weinshenker BG, Wingerchuk DM, Green AJ, Bennett JL, Kim HJ, Pittock SJ, Fujihara K, Paul F, Cutter G, Marignier R, Aktas O, Hartung HP, She D, Smith M, Rees W, Patterson K, Cimbora D, Katz E, Cree BA. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. Mult Scler. 2023 07; 29(8):945-955.
-
Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De S?ze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023 07; 10(4).
-
Marin AI, Zarubina AV, Bennett JL, Subramanian PS. Seropositive Neuromyelitis Optica Spectrum Disorder Presenting With Optic Nerve Sheath Enhancement and Optic Disc Edema Resembling Optic Nerve Sheath Meningioma. J Neuroophthalmol. 2024 Sep 01; 44(3):e350-e352.
-
Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BA. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2023 09; 94(9):757-768.
-
Pittock SJ, Barnett M, Bennett JL, Berthele A, de S?ze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 06; 93(6):1053-1068.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|